WaveLight® Refractive Myopic Study

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Alcon Research
ClinicalTrials.gov Identifier:
NCT01941498
First received: September 10, 2013
Last updated: October 2, 2015
Last verified: October 2015
  Purpose
The purpose of this study is to evaluate outcomes of subjects undergoing myopic surgery using the WaveLight® Refractive Suite (Excimer EX500 and Femtosecond FS200 lasers).

Condition Intervention
Refractive Error
Device: Wavelight® Refractive Suite
Procedure: LASIK surgery

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective, Global, Multi-Center Study for the Evaluation of Outcomes on Subjects Undergoing Myopic Treatments Using the WaveLight® Refractive Suite

Resource links provided by NLM:


Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Least Squares Mean Difference in Binocular UCVA at 1 Month Post-Treatment and Pre-Treatment Binocular BCVA [ Time Frame: Month 1 ] [ Designated as safety issue: No ]
    Visual acuity (VA) with corrective devices (BCVA) was assessed binocularly (both eyes together) pre-treatment and subtracted from VA without spectacles or other visual corrective devices (UCVA) assessed binocularly at 1 month post-treatment. VA was measured at a distance of 4 meters and reported in logMAR (logarithm of the minimum angle of resolution), with 0.00 logMAR corresponding to 20/20 Snellen. A negative value indicates an improvement in VA from pre-treatment to Month 1.


Secondary Outcome Measures:
  • Mean Difference Between Achieved and Target Corneal Flap Thickness as Assessed by OCT [ Time Frame: Operation/Surgery (Day 1), Month 1 Postoperative, Month 6 Postoperative ] [ Designated as safety issue: No ]
    The expected flap thickness as determined pre-operatively was subtracted from the achieved flap thickness as assessed by optical coherence tomography (OCT) (ie, an imaging method using light to capture three-dimensional images). A positive number represents a postoperative flap thickness that is thicker than the expected flap thickness and vice versa for a negative number.

  • Mean Manifest Refraction (Sphere) [ Time Frame: Baseline (Day 0), Operation/Surgery (Day 1), Month 1 Postoperative, Month 3 Postoperative, Month 6 Postoperative ] [ Designated as safety issue: No ]
    Manifest refraction was performed under photopic lighting conditions using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart at 4 meters. The subject was manually refracted to his/her best correction using a phoropter. Each eye individually contributed to the mean.

  • Mean Manifest Refraction (Cylinder) [ Time Frame: Baseline (Day 0), Month 1 Postoperative, Month 3 Postoperative, Month 6 Postoperative ] [ Designated as safety issue: No ]
    Manifest refraction was performed under photopic lighting conditions using an ETDRS chart at 4 meters. The subject was manually refracted to his/her best correction using a phoropter. Each eye individually contributed to the mean.

  • Mean Laser Treatment Time [ Time Frame: Day 0 (surgery) ] [ Designated as safety issue: No ]
    Treatment time with Excimer EX500 and Femtosecond FS200 lasers, measured in seconds.

  • Mean Total Laser Treatment Time [ Time Frame: Day 0 (surgery) ] [ Designated as safety issue: No ]
    Total treatment time with Excimer EX500 and Femtosecond FS200 lasers, measured in seconds. Total duration for both eyes was calculated as sum of duration for the right eye and left eye.

  • Mean Response: "Rate Your Vision, Over the Past 4 Weeks, With NO Glasses or Contact Lenses" [ Time Frame: Baseline (Day 0), Month 1 Postoperative, Month 6 Postoperative ] [ Designated as safety issue: No ]
    As recorded by the subject on the the Refractive Status and Vision Profile (RSVP), a self-reported questionnaire used to measure vision-related health status in persons with refractive error, on a scale from 0 (completely blind) to 10 (perfect vision).

  • Percent Response by Category: "In the Past 4 Weeks, to See Far Away, I Wore..." [ Time Frame: Baseline (Day 0), Month 1 Postoperative, Month 6 Postoperative ] [ Designated as safety issue: No ]
    As recorded by the subject on the RSVP questionnaire, where n/a means no use of glasses or contact lenses.

  • Percent Response by Category: "I Worry About my Vision" [ Time Frame: Baseline (Day 0), Month 1 Postoperative, Month 6 Postoperative ] [ Designated as safety issue: No ]
    As recorded by the subject on the RSVP questionnaire

  • Percent Response by Category: "My Vision Is a Concern in My Daily Life" [ Time Frame: Baseline (Day 0), Month 1 Postoperative, Month 6 Postoperative ] [ Designated as safety issue: No ]
    As recorded by the subject on the RSVP questionnaire

  • Percent Response by Category: "Driving at Night" [ Time Frame: Baseline (Day 0), Month 1 Postoperative, Month 6 Postoperative ] [ Designated as safety issue: No ]
    As recorded by the subject on the RSVP questionnaire, where 0 is "Not applicable", 1 is "No difficulty at all", 2 is "A little difficulty", 3 is "Moderate difficulty", 4 is "Severe difficulty" and 5 is "So much difficulty that I did not do the activity with this alternative".

  • Mean Contrast Sensitivity (CS) [ Time Frame: Baseline (Day 0), Day 1 Postoperative, Month 1 Postoperative, Month 3 Postoperative, Month 6 Postoperative ] [ Designated as safety issue: No ]
    Contrast sensitivity (ie, the ability to detect slight changes in luminance before they become indistinguishable) was assessed binocularly with distance manifest correction in place and uncorrected. Contrast sensitivity was assessed at spatial frequencies of 3, 6, 12, and 18 cycles per degree (cpd), where 3.0 cpd = A, 6.0 cpd = B, 12.0 cpd = C, and 18.0 cpd = D. Raw scores were log transformed. A higher numeric value represents better contrast sensitivity.

  • Wavefront Aberrometry [ Time Frame: Baseline (Day 0), Month 6 Postoperative ] [ Designated as safety issue: No ]
    Wavefront aberrations (optical imperfections of the eye that prevent light from focusing perfectly on the retina, resulting in defects in the visual image) were measured using a commercially available system. Higher order aberrations (i.e., spherical aberrations, coma, and trifoil) are defined as optical imperfections which cannot be corrected by any reliable means of present technology.

  • Corneal Curvature as Measured by Keratometry [ Time Frame: Baseline (Day 0), Month 1 Postoperative, Month 3 Postoperative, Month 6 Postoperative ] [ Designated as safety issue: No ]
    Corneal curvature was assessed by a commercially available system and measured in diopters.


Enrollment: 104
Study Start Date: September 2013
Study Completion Date: August 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: WaveLight Refractive Suite
LASIK surgery (laser in situ keratomileusis) per standard of care
Device: Wavelight® Refractive Suite
Excimer EX500 and Femtosecond FS200 lasers (Wavelight® Refractive Suite) used during LASIK surgery for corneal flap creation and corneal ablation
Procedure: LASIK surgery
Surgical procedure for treating refractive error based on corneal reshaping

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Willing and able to understand and sign an informed consent form.
  • Have refractive error (in both eyes) that requires refractive surgery.
  • Willing to undergo LASIK surgery using the Wavelight® Refractive Suite.
  • Myopia between 0.00 to -12.0 diopters pre-operatively.
  • Astigmatism between 0.00 to +6.00 diopters pre-operatively.
  • Willing and able to attend post-operative examinations per protocol schedule.
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

  • Participation in a clinical study within the last 30 days.
  • History of previous corneal surgery in either eye.
  • Multifocal ablations in either eye.
  • PRK or PTK surgery in either eye.
  • Suffering from acute or recurring eye diseases in either eye, such as corneal ulcers, cataract, etc.
  • Any ocular disease and/or condition that, in the Investigator's clinical judgment, may put subject at significant risk, compromise study results, or interfere significantly with subject's participation in the study.
  • Unable to discontinue contact lens wear as specified in protocol.
  • History of Herpes simplex or Herpes zoster keratitis.
  • Active ocular rosacea.
  • Lyme disease.
  • History of dry eye that is unresponsive to treatment.
  • Severe ocular allergies.
  • Other medical conditions and use of medications as specified in protocol.
  • Pregnant or planning to become pregnant during the study.
  • Other protocol-specified exclusion criteria may apply.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01941498

Sponsors and Collaborators
Alcon Research
Investigators
Study Director: Clinical Manager, GMA, Surgical Alcon Research
  More Information

No publications provided

Responsible Party: Alcon Research
ClinicalTrials.gov Identifier: NCT01941498     History of Changes
Other Study ID Numbers: A01353 
Study First Received: September 10, 2013
Results First Received: February 1, 2015
Last Updated: October 2, 2015
Health Authority: United States: Institutional Review Board
Ireland: Research Ethics Committee
Germany: Ethics Commission

Keywords provided by Alcon Research:
nearsighted
farsighted
astigmatism
LASIK
refractive surgery
WaveLight

Additional relevant MeSH terms:
Refractive Errors
Eye Diseases

ClinicalTrials.gov processed this record on February 08, 2016